Evotec

Tubulis generates uniquely matched protein-drug conjugates by combining proprietary novel technologies with disease-specific biology. Their goal is to expand the therapeutic potential of antibody drug conjugates (ADCs) ushering in a new era and delivering better outcomes for patients.

Centauri Therapeutics is a UK-based biotechnology company dedicated to discovering and developing innovative molecules aimed at combating life-threatening diseases. The company utilizes its proprietary Alphamer technology, which involves chemically synthesized molecules that redirect naturally occurring antibodies to specific pathogens, enhancing the immune response against infections. Each Alphamer consists of two components: one binds to a cell-surface target on the pathogen, while the other presents specific epitopes that engage circulating antibodies. This approach has demonstrated the ability to trigger an immediate antibacterial immune response, effectively clearing infections. Centauri Therapeutics' flexible Chemistry Platform allows for the synthesis of these bifunctional molecules, which are applicable in treating various infectious diseases. Additionally, the company has formed a joint venture, Avvinity Therapeutics, with Horizon Discovery to advance immuno-oncology initiatives, combining Centauri's expertise in Alphamer technology with Horizon's capabilities in gene editing and oncology. Through collaborations in aptamer selection, drug discovery, chemistry, and immunology, Centauri Therapeutics aims to enhance its impact in the field of immunotherapy.

IMIDomics is a unique company tackling Immune-Mediated Inflammatory Diseases (IMIDs). As an innovative leader in discovery and application of biomarkers and new targets to monitor and cure IMIDs, we create value through the combination of the world's largest IMID biobank, extensive relevant clinical expertise, high-throughput genomic and genetic analysis, and intellectual property. IMIDomics is located at Vall d'Hebron Hospital in Barcelona, Spain and on the HudsonAlpha Institute campus in Huntsville, Alabama.

Topas Therapeutics GmbH is a biotechnology company based in Hamburg, Germany, focused on developing nanoparticle-based therapeutics to address significant unmet medical needs, particularly in autoimmune diseases, allergies, and anti-drug antibodies. The company utilizes its proprietary Topas Particle Conjugates technology platform to induce antigen-specific immune tolerance by leveraging the liver's natural immunological processes. This approach targets liver sinusoidal endothelial cells to promote tolerance against blood-borne antigens. Topas is advancing several clinical-stage programs, with its lead candidate, TPM203, currently in clinical testing for pemphigus vulgaris, an orphan disease. Other therapeutic programs under development include treatments for celiac disease, Type 1 diabetes, and multiple sclerosis. The company has established research collaborations with Eli Lilly and Company and Boehringer Ingelheim to enhance its capabilities in antigen-specific tolerance induction and anti-drug antibodies, respectively. Topas Therapeutics was incorporated in 2013 and is dedicated to finding innovative solutions for chronic immunological conditions.

OxVax Ltd. is a spin-out from the University of Oxford that specializes in developing an advanced next-generation dendritic cell vaccine platform aimed at treating solid tumor cancers. The company utilizes induced pluripotent stem cells (iPSC) to generate CD141+ dendritic cells, a unique subset known for their promising properties in cancer immunotherapy. This innovative approach seeks to provide effective treatment options for patients facing difficult-to-treat cancers, leveraging the potential of these specialized cells to enhance immune responses against tumors.

Exscientia is applying AI and big data processing to accelerate drug discovery and development. At the forefront of small molecule drug discovery. They are the first company to automate drug design, surpassing conventional human endeavor. Their AI-driven systems actively learn best practice from vast repositories of discovery data and are further enhanced with knowledge acquired from seasoned drug hunters. With better information to hand than any researcher could acquire individually, their knowledge-driven systems design millions of novel, project-specific compounds and pre-assess each for predicted potency, selectivity, ADME and other key criteria. From this, a selection of the best, information-rich compounds are selected for synthesis and assay. With new experimental data generated, the results are integrated and the next design cycle initiated. Rapid design-make-test cycles ensure unparalleled progress towards desired project goals. Exscientia has already delivered exceptional productivity, generating candidates in roughly one-quarter of the time of traditional approaches.

Operator of a biotechnological therapeutic platform intended to provide financial assistance and operational excellence to early-stage projects. The company's platform identifies, selects, and incubates early-stage biotechnology projects that focus on selected therapeutic areas such as rare diseases, neurological disorders, oncology, and immunology, enabling startups to further develop their medicinal and drug research process.

Blacksmith Medicines developing medicines targeting metal-dependent enzymes found in human physiology. Over 30% of known enzymes are metalloenzymes, covering all major enzyme classes: oxidoreductases, transferases, hydrolases, lyases, isomerases, and ligases. Metal ions, including magnesium, zinc, iron, manganese and copper, are the essential ingredient in these metalloenzymes.

Autobahn Labs is a biotechnology company that accelerates the development of novel therapeutics. It is a collaboration between a Samsara BioCapital-led investor syndicate and Evotec. By combining Samsara's long-term investment philosophy with Evotec’s world-class drug discovery and development capabilities, they believe they can improve patient health by identifying exciting early-stage academic research projects that can spark the development of new therapeutics. It was founded in 2018 and is based in Palo Alto, California.

Exscientia is applying AI and big data processing to accelerate drug discovery and development. At the forefront of small molecule drug discovery. They are the first company to automate drug design, surpassing conventional human endeavor. Their AI-driven systems actively learn best practice from vast repositories of discovery data and are further enhanced with knowledge acquired from seasoned drug hunters. With better information to hand than any researcher could acquire individually, their knowledge-driven systems design millions of novel, project-specific compounds and pre-assess each for predicted potency, selectivity, ADME and other key criteria. From this, a selection of the best, information-rich compounds are selected for synthesis and assay. With new experimental data generated, the results are integrated and the next design cycle initiated. Rapid design-make-test cycles ensure unparalleled progress towards desired project goals. Exscientia has already delivered exceptional productivity, generating candidates in roughly one-quarter of the time of traditional approaches.

leon nanodrugs a specialised product development company dedicated to developing a pipeline of enhanced versions of existing drug products, and providing services to enable pre-clinical and clinical stage formulations for their clients NCEs or branded established drugs. leon-nanodrugs offers access to the next generation of nano-formulated drugs with meaningful differentiation and added patient benefits. They specialize in improving the bioavailability of poorly water soluble drugs by using leon’s proprietary MJR® Technology platform to create either polymeric or crystalline nanoparticles.

Immunitas Therapeutics, Inc. is focused on developing targeted therapies for cancer patients through innovative single-cell analyses. Founded in 2019 and based in Cambridge, Massachusetts, the company utilizes a single-cell sequencing platform to explore the biology of immune cells within human tumors. This approach allows Immunitas to identify novel drug targets rooted in human biology and create key biomarkers that assist in selecting patients who may benefit from their therapies. By translating laboratory findings into clinical applications, Immunitas aims to address longstanding challenges in oncology and improve treatment options for complex cancers. The company is advancing multiple programs toward early human studies, leveraging expertise in antibody discovery and engineering to develop effective treatments.

Aeovian Pharmaceuticals is a San Francisco-based biopharmaceutical company focused on the research and development of innovative therapeutics for rare and age-related diseases. Founded in 2012, the company aims to discover and commercialize compounds that modulate key molecular pathways, specifically targeting the mTORC1 and mTORC2 pathways. By addressing the underlying causes of disease initiation and progression—such as oxidative, cellular, and environmental stress—Aeovian Pharmaceuticals seeks to provide effective treatments that improve patient outcomes.

Breakpoint Therapeutics GmbH, located in Hamburg, Germany, specializes in the discovery and development of innovative anti-cancer drugs. The company focuses on targeting the DNA damage response (DDR) in cancer cells, specifically aiming to disrupt pathways related to DNA repair and replication stress tolerance. By doing so, Breakpoint Therapeutics seeks to advance first-in-class oncology drugs that not only complement existing treatments, such as PARP inhibitors, but also address the challenge of therapy-resistant cancers. Through its research and development efforts, the company aspires to enhance treatment options for patients facing difficult-to-treat cancer types.

Just Evotec Biologics was founded in 2014 and acquired by Evotec in 2019. The company has an intense focus on the design of innovative and integrated technologies to accelerate the development of biotherapeutics and reduce their manufacturing cost. Core strengths include antibody discovery, molecular design, process and product design and manufacturing plant design.

Celmatix is a preclinical-stage women’s health biotech focused uniquely on ovarian biology. With a lead program in ovarian senescence and collaborations in PCOS and non-hormonal contraception with industry leaders, Celmatix is addressing areas of high unmet need by developing the next generation of interventions and pioneering advancements in ovarian health.

Exscientia is applying AI and big data processing to accelerate drug discovery and development. At the forefront of small molecule drug discovery. They are the first company to automate drug design, surpassing conventional human endeavor. Their AI-driven systems actively learn best practice from vast repositories of discovery data and are further enhanced with knowledge acquired from seasoned drug hunters. With better information to hand than any researcher could acquire individually, their knowledge-driven systems design millions of novel, project-specific compounds and pre-assess each for predicted potency, selectivity, ADME and other key criteria. From this, a selection of the best, information-rich compounds are selected for synthesis and assay. With new experimental data generated, the results are integrated and the next design cycle initiated. Rapid design-make-test cycles ensure unparalleled progress towards desired project goals. Exscientia has already delivered exceptional productivity, generating candidates in roughly one-quarter of the time of traditional approaches.

Exscientia is applying AI and big data processing to accelerate drug discovery and development. At the forefront of small molecule drug discovery. They are the first company to automate drug design, surpassing conventional human endeavor. Their AI-driven systems actively learn best practice from vast repositories of discovery data and are further enhanced with knowledge acquired from seasoned drug hunters. With better information to hand than any researcher could acquire individually, their knowledge-driven systems design millions of novel, project-specific compounds and pre-assess each for predicted potency, selectivity, ADME and other key criteria. From this, a selection of the best, information-rich compounds are selected for synthesis and assay. With new experimental data generated, the results are integrated and the next design cycle initiated. Rapid design-make-test cycles ensure unparalleled progress towards desired project goals. Exscientia has already delivered exceptional productivity, generating candidates in roughly one-quarter of the time of traditional approaches.

Aptuit, LLC specializes in integrated drug development services, covering the entire spectrum from early discovery to mid-phase development in the pharmaceutical industry. The company offers a wide range of services, including drug design and discovery, active pharmaceutical ingredient (API) development and manufacturing, solid-state chemistry, and preclinical programs that comply with GLP and GMP standards. With facilities located in the UK, Italy, and Switzerland, Aptuit provides its bio-pharma partners with comprehensive scientific expertise and efficient solutions aimed at accelerating the transition of drugs into clinical trials. The firm is partnered with Welsh, Carson, and Anderson & Stowe, a prominent private equity investor, enhancing its capabilities in drug discovery and production.

Forge Therapeutics, Inc is a biotechnology company discovering and developing novel therapeutics using an innovative chemistry platform targeting metalloproteins. Forge uses a proprietary approach combining bioinorganic (study of metals in biology) and medicinal chemistry to generate selective inhibitors of this large class of targets.

Eternygen GmbH is a biotechnology company based in Berlin, Germany, with an additional office in the United Kingdom. Founded in June 2012, the company specializes in the research and development of innovative drugs aimed at treating dietary-related metabolic diseases, which have seen a significant rise in prevalence over recent decades. Eternygen focuses on small molecule inhibitors targeting the sodium-coupled citrate transporter (NaCT), a crucial regulator of lipid metabolism linked to conditions such as fatty liver, diabetes, and obesity. By addressing the underlying metabolic failures associated with these diseases, Eternygen aims to develop safe and effective therapies that can enhance patient care in managing these widespread health issues.

Cyprotex PLC is a contract research organization that specializes in providing in vitro and in silico services related to absorption, distribution, metabolism, excretion, and toxicity (ADMET) as well as pharmacokinetics (PK) information. Founded in 1999 and headquartered in Macclesfield, United Kingdom, Cyprotex offers a range of services including in vitro metabolism, permeability studies, toxicology assessments, and physicochemical profiling. Their toxicology services encompass various assays such as cardiotoxicity, neurotoxicity, and genotoxicity, while their ADME and PK offerings include bioanalysis and prodrug evaluations. The company also features advanced modelling solutions like chemPK and chemTox, which predict pharmacokinetic parameters and toxicity based on chemical structures. Cyprotex serves a diverse clientele across pharmaceutical, biotechnology, cosmetics, agrochemical, and academic sectors in the UK, Europe, North America, and beyond.

Carrick Therapeutics, Ltd., founded in 2015 and based in Dublin, Ireland, focuses on developing innovative cancer therapeutics aimed at transforming cancer treatment. The company targets specific molecular pathways associated with aggressive and resistant cancer forms, allowing for early detection of predictive biomarkers. This approach facilitates timely treatment initiation for patients, enhancing the potential for improved outcomes in cancer care.

Sanofi is a global healthcare company headquartered in Paris, France, engaged in the research, development, manufacturing, and marketing of a wide range of therapeutic solutions. The company specializes in areas such as diabetes, oncology, neurology, immunology, and rare diseases. Its product portfolio includes prescription medications for conditions like multiple sclerosis, hemophilia, and various cancers, as well as diabetes treatments and cardiovascular drugs. Sanofi also offers vaccines and over-the-counter products for allergies, pain, and respiratory issues. The company has undergone significant transformations, including mergers that have shaped its current identity, and it operates in over 100 countries worldwide. Sanofi collaborates with various organizations to enhance its research and development efforts, aiming to provide innovative treatments that address patient needs.

Euprotec is a collaborative preclinical Contract Research Organisation.

Bionamics GmbH is a Hamburg-based asset management company specializing in the life sciences sector. It focuses on bridging the gap between innovative research projects and the pharmaceutical industry's requirements for pre-clinical and clinical development programs. Bionamics acquires and licenses life science assets in the pre-clinical phases, providing essential project management services to pharmaceutical companies. Through its strategic approach, Bionamics aims to facilitate the advancement of promising research into viable therapeutic solutions.

Cell Culture Service GmbH (CCS), a Hamburg-based company which supports the cell culture needs of a world-wide customer base of biotech and Pharmaceutical companies. CCS is one of the leading suppliers of custom cells and cell-based reagents such as recombinant assay cell lines, assay-ready Frozen Instant Cells, qualified membranes, and proteins for high throughput screening with more than ten years experience in bulk cell production.

Compound Focus, Inc. offers molecule compound management services for liquid and solid compounds.

KINAXO Biotechnologies is a privately-held biotechnology company based in Munich/Martinsried, Germany. They are a service company specializing in chemical proteomics methods to support the successful development of small molecule drugs. As a spin-off of the Max Planck Institute of Biochemistry in Martinsried, they continuously expand and improve their technology platform in collaboration with the leading Max Planck laboratories of Axel Ullrich, Henrik Daub and Matthias Mann. KINAXO offers its clients extensive experience in cellular target profiling and other chemical proteomics applications.

Develogen is a biology-driven drug discovery company that is engaged in the development of therapies for diabetes and obesity. The company was founded in 1995 and is based in Georgia, United States.

Evotec (India) Private Limited provides drug discovery and development services for pharmaceutical, biotech, and fine chemical industries.

Renovis, Inc. is a biopharmaceutical company developing drugs to treat neurological diseases and disorders. The Company is currently developing products for acute ischemic stroke, for the treatment of neuropathic pain, and for the treatment of acute post-operative pain.

Evotec Neurosciences GmbH engages in the discovery and development of small molecule drugs.

Oxford Asymmetry International operates as an outsourcing arm for pharmaceutical companies.